Vernalis PLC Share News (VER)
VER Share
VER Share
VER Share
VER Share
VER
VER Share
VER Broker
VER Directors
VER Financial
VER
VER Short
VER
Strong royalties from its migraine treatment Frovatriptan helped Vernalis narrow losses in the year to 31 December. Pre-tax losses before exceptional items narrowed to £5.3m from £13.4m on revenues that rose to £14.2m from £13m. Vernalis regained 100% of royalties from Frovatriptan in March 2010 f
Read moreReports that Vivendi will not be willing to pay any more than £6bn for Vodafone's 44% stake in the French mobile phone operator SFR has hit the mobile phone giant's share price. Vivendi owns the controlling stake in SFR. Vodafone is also talking to Verizon Communications about pooling certain op
Read moreWolfson Microelectronics is lower after non-executive director and co-founder Dr Alastair Milne raised £725,000 from a share disposal. Dr Milne, who co-founded Wolfson in 1984 and was chief executive until 2007, sold 250,000 shares at 290p each. He still owns 2.84m shares, which is equivalent to 2
Read moreAEA Technology has returned from suspension following the announcement of its deal to acquire Eastern Research Group Inc financed by a heavily discounted fundraising. The shares were suspended yesterday but trading was restored this morning and they lost more than half of their value. The placing
Read moreBlinds specialist Titon's revenues for the 3 months to June were 19% higher than the corresponding period last year, with UK sales 15% higher and the rest of the world 37% higher. Growth in the UK came from higher sales of mechanical ventilation systems. There were also increased sales volumes in
Read moreTorotrak has warned that the outcome for the year to March 2011 is still reliant on potential licence discussions and whether Allison transmission takes-up further options. Transmission systems developer Torotrak has recognised £700,000 of licence income from Allison so far this year. The develo
Read moreLONDON (Dow Jones)--Vernalis PLC (VER.LN), a development stage pharmaceutical company, said Thursday that it made pretax loss of GBP8.91 million for the half year ended June 30, compared with GBP6.23 million. MAIN FACTS: -Revenue GBP7.2 million versus GBP5.7 million, up 26% -Loss per sha
Read moreBy Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Biogen Idec Inc.'s (BIIB) move to end development of an experimental Parkinson's Disease drug is the latest in a spate of pipeline setbacks for the biotech company. The Weston, Mass., company, along with partner Vernalis PLC (V
Read moreDow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps KCOM GROUP PLC (KCOM.LN), a telecommunications firm, said Friday it has agreed to make pension deficit repayments worth GBP21 million over the next three
Read moreInstrumentation and controls company Spectris is higher after a positive trading update and broker KBC Peel Hunt switching from a hold to buy recommendation. Spectris expects full year results to be ahead of expectations after an 'encouraging' first half. KBC Peel Hunt has upgraded its profit fore
Read moreDow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps VERNALIS PLC (VER.LN), a drug developer, Friday said it is searching for new drugs to add to its portfolio following the end of one of its most advanced
Read moreBy Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Drug developer Vernalis PLC (VER.LN) Friday said it is searching for new drugs to add to its portfolio following the end of one of its most advanced programs. Vernalis and Biogen Idec Inc. (BIIB) said Friday they stopped develop
Read more(Adds detail and analyst comment.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Drug developer Vernalis PLC (VER.LN) Friday said it stopped development of one of its most advanced experimental medicines following a review of laboratory data, in its second setback this year
Read moreLONDON (Dow Jones)--Vernalis PLC (VER.LN), a development stage pharmaceutical company, said Friday that the company and its partner, Biogen Idec Inc. (BIIB), have discontinued development of V2006/BIIB014, also known as vipadenant, and will continue its novel A2A receptor antagonist program for Park
Read moreShares in Gresham Computing have fallen ahead of the software company's exclusion from the TechMARK Focus index next Monday. There was a spike downwards in the Gresham share price just before midday even though there has not been a trade since just after 10am. FTSE said last week that Gresham, p
Read more
